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INTRODUCTION
Cell culture and in vitro transporter-mediated uptake or efflux assays
Caco-2 cell permeability was used for the estimation of absorption of PNU-288034, conducted according to a previously reported method (Lai et al., 2007) . To evaluate the involvement of drug transporters in the renal secretion of PNU-288034, control and human renal transporter gene-transfected HEK293 cell lines (Feng et al., 2008; Matsushima et al., 2009 ) were used to conduct the drug uptake assays. HEK cells were grown in DMEM containing 10% FBS (non-dialyzed), 100 units/mL penicillin, 100 μ g/mL streptomycin, 2 mM L-glutamine, and either 50 µg/mL hygromycin B (hOAT1, hOAT3, hOCT2) or 200 µg/mL geneticin (hMATE1 and hMATE2-K). The assays were carried out in 96-well poly-D-lysine-coated plates (BD Bioscience, San Jose, CA) with cells seeded at 300K cells/cm 2 and grown for 24 h before each experiment. The OATand OCT-transfected cells were washed and pre-incubated with 100 μ L of HBSS for 15 min followed by incubation with 100 μ L HBSS buffer containing 10 µM PNU-288034 without or with inhibitors at 37°C for 1 min. For experiments with MATE transporters, cells were washed and pre-incubated with 100 μ L of uptake buffer (145 mM NaCl, 3 mM KCl, 1 mM CaCl 2 , 0.5 mM MgCl 2 , 5 mM glucose, 5 mM HEPES, pH 7.4) either alone or with 30 mM ammonium chloride (for stimulation of uptake through intracellular acidification) for 20 min, followed by incubation with 100 μ L of uptake buffer containing 10 µM PNU-288034 without or with inhibitors at 37°C for 2 min. Cellular uptake was terminated by washing the cells three times with 100 μ L ice-cold incubation buffer. The cells were lysed directly on the plate using a 50% methanol solution containing the internal standard (50 nM carbamazepine). After centrifugation the supernatant and PNU-288034 standards were subjected to LC-MS/MS analysis as described below. The protein This article has not been copyedited and formatted. The final version may differ from this version.
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Concentration-dependent uptake was also characterized in HEK-hOAT3 (5 -160 μ M PNU-288034) and HEK-hMATE1 (6 -400 μ M PNU-288034) cells in order to determine the kinetics of drug transport. The incubations were performed as described above and terminated after 1 min, which was found to be an optimal time point for initial rate determination for both transporters. The transporter-mediated uptake was obtained by subtracting the uptake velocity in control cells from that in transfected cells. days in MEM-α containing 10% FBS, 100 units/mL penicillin, 100 µg/mL streptomycin, 2 mM L-glutamine, and 0.1 mM MEM non-essential amino acids. On the day of the study, the cell monolayers were rinsed twice with Buffer B (HBSS containing 25 mM Dglucose and 20 mM HEPES, pH 7.4), and pre-incubated for 30 min at 37ºC. Buffer B containing 2 μM PNU-288034 was applied to apical or basal (donor) chambers to initiate the transport. The incubation was performed for 2 h at 37 ο C. Aliquots were removed from both donor and receiver chambers at the end of the incubation and mixed with one volume of ACN containing internal standard. was used to determine the involvement of P-gp or BCRP (Xiao et al., 2006) .
Distribution and clearance of PNU-288034 in Oat3 gene knockout mice
Oat3 gene knockout mice (Oat3(-/-)) were generated at Pfizer PGRD (Groton, CT) after microinjection of slc22a8 targeted embryonic stem cells (Deltagen Inc, San
Carlos, CA) into C57BL/6 blastocyst stage embryos (Charles River Laboratories, Wilmington MA), and subsequent breeding using previously described methods (Zaher et al., 2008) . The homozygous knockout mice and WT age-matched C57BL mice (n=4/group) were used to investigate the impact of Oat3 transporter deficiency on PNU-288034 exposure. Mice were allowed food and water ad libitum. PNU-288034 was formulated in 10% 2-hydroxypropyl-β-cyclodextrin to a 1 mg/mL concentration. Dosing solutions were sonicated 5-10 min and transferred to Alzet 2001D pumps and surgically inserted under the skin in male WT and Oat3(-/-) mice. The Alzet pumps delivered compound at 8 μL/h subcutaneously. Animals were sacrificed 24 h after pump insertion, and blood samples and kidneys were collected for bioanalysis. Blood was transferred to EDTA tubes, centrifuged, and plasma transferred to sample plates. Kidneys were homogenized with 5 volumes of water. Plasma and kidney homogenate samples were processed for LC-MS/MS analysis by protein precipitation with a 2-fold excess of ACN This article has not been copyedited and formatted. The final version may differ from this version. was determined from plasma samples collected before and during treatment with inhibitors such that each rat served as its own control. The plasma clearance of inulin in rats was taken as equal to the GFR. Similar renal transporter inhibition studies were also conducted in male cynomolgus monkeys. At day 1, the single IV dose pharmacokinetics of PNU-288034 at 10 mg/kg was determined for 3 monkeys. After a two week wash-out period, probenecid was orally administered to each animal every 6 h at 30 mg/kg starting 24 h prior to the IV dose of 10 mg/kg PNU-288034. At designated time points, blood was collected via an indwelling catheter and the plasma was subjected to LC-MS/MS analysis.
LC-MS/MS analysis for PNU-288034
Quantitation of PNU-288034 was conducted by LC-MS/MS analysis using either an API-3000 or API-4000 triple quadrupole mass spectrometer with an atmospheric 
Statistical Analysis
Statistical differences were determined using the unpaired or paired Student's t test.
Differences were considered significant at the level of p≤0.05.
Pharmacokinetic calculations
Concentration-time profiles were analyzed using standard non-compartmental 
RESULTS
In vitro ADME properties of PNU-288034
Several in vitro studies were conducted to estimate the absorption and metabolism of PNU-288034 in both preclinical species and human. Drug absorption was assessed using the well-characterized Caco-2 cell model. Based on these results, PNU-288034 was classified as having low to moderate permeability with Caco-2 apical to basolateral permeability of 2.7X10 -6 cm/s and basolateral to apical permeability of 8.75X10 -6 cm/s (efflux ratio=3.3). To evaluate the contribution of hepatic metabolism to overall drug clearance, 5 μM PNU-288034 was incubated with liver microsomes from rat, dog, monkey, and human. The percentage of parent PNU-288034 remaining was measured at 30 min post incubation. The metabolism-dependent disappearance of PNU-288034 was found to be negligible during the 30 min incubation with liver microsomes from all species tested (data not shown). These results suggested that the compound would not be significantly cleared by hepatic P450-dependent metabolism.
Human pharmacokinetics
At all oral doses of a hand-filled capsule formulation, PNU-288034 was found to be relatively well absorbed (>64%) with a T max of 2 hours ( Figure 2A ). The AUC 0-∞ and C max were approximately dose proportional over the dose range of 100 to 1000 mg ( Figure 2B and Table 1 ). The urinary recovery of unchanged compound was decreased at higher doses, but was never less than 64% (Table 1) . Oral bioavailability ( ranging from 390 to 530 mL/min (~ 3-4 times GFR) was observed in all dose groups ( Figure 2C and Table 1 ), thereby suggesting renal secretion is the major route for PNU-288034 elimination.
Pharmacokinetics in preclinical species
The IV and oral pharmacokinetics of PNU-288034 were evaluated in mouse, rat, and dog, while the monkey IV data was obtained from a control group in the chemical inhibition study. As shown in Table 2 , plasma clearance in mouse was 32.9 mL/min/kg with a volume of distribution (V ss ) of 1.38 L/kg and mean residence time (MRT) of 0.7 h.
Intravenous plasma clearance in rat, dog, and monkey was 18.9, 5.58, and 6.55 mL/min/kg, respectively, with a distributional volume ranging from 0.57 to 1.3 L/kg.
Following oral administration of PNU-288034, rapid absorption was observed (T max of 0.167 to 0.5 h) in the mouse, rat, and dog with high oral bioavailability ranging from 73 to 96%, which is consistent with the observations in humans. More than 73% of unchanged compound was recovered in the urine of rat and dog, whereas only 42% was recovered in monkey ( Table 2 ). The ratio of CL r /GFR is shown in Figure 3 . The renal clearance values were between 2-and 4-fold over GFR in rat, monkey, and human, suggesting active tubular secretion of the compound. Although the unchanged PNU-288034 was predominately eliminated in the urine in dog (95% in IV and 88.7% in PO), the ratio of CL r /GFR was close to 1, suggesting that dog does not display this apparent active renal secretion phenomenon (Figure 3) . The results of the pharmacokinetic linearity experiments for PNU-288034 in rat are given in Table 3 . The AUC 0-∞ and C max This article has not been copyedited and formatted. The final version may differ from this version. increased proportionally with increasing dose, with the recovery of unchanged compound in rat urine declining to 50.8% at the highest dose tested (107 mg/kg).
In vitro renal transport of PNU-288034
The uptake of PNU-288034 was examined in human OAT1, OAT3, OCT2, MATE1, and MATE2-K gene-transfected HEK293 cells. As shown in Figure 4 , uptake was significantly increased in HEK-hOAT3 cells when compared to that in control cells, suggesting that PNU-288034 is a substrate of OAT3, but not a substrate of the OAT1 or OCT2 transporters. Moreover, the OAT3-mediated PNU-288034 uptake was significantly inhibited by 10 µM probenecid. The uptake of PNU-288034 in HEK-hOAT3 cells was further characterized and found to be saturable with a K m =44 ± 5 µM ( Figure 5A ).
Transport by hMATE1 and hMATE2-K was also examined in an in vitro setting. Uptake The P-gp-and BCRP-mediated efflux was confirmed in bi-directional transport assays using human MDR1 or BCRP gene-transfected MDCK cell lines. The ratio of efflux ratios in MDCK-MDR1 and -BCRP cells over that in MDCK-WT cells was 2.49 ± 0.41 and 3.27 ± 0.39, respectively, suggesting that PNU-288034 is a P-gp and BCRP substrate (Table 4) .
This article has not been copyedited and formatted. The final version may differ from this version. (-/-) ) and WT mice were pump infused with 1 mg/mL PNU-288034 at 8 µL/h and the plasma concentration was evaluated upon termination of the infusion. As shown in Figure 6 , the plasma concentration of PNU-288034 in Oat3(-/-) mice was increased to 160% of the concentration in WT mice (p<0.05), suggesting that the Oat3 function deficiency in the knockout mice reduces active renal secretion of PNU-288034. The disposition of PNU-288034 in the kidney of pump-infused mice was also investigated.
An accumulation of PNU-288034 in kidney tissue was not observed in Oat3(-/-) mice, as compared to that in WT mice (data not shown).
Pharmacokinetics of PNU-288034 co-administered with probenecid in monkey and probenecid or cimetidine in rat
The effect of renal transporter inhibition on the disposition of PNU-288034 in monkeys co-administered probenecid, and rats co-administered probenecid or cimetidine was also investigated. Probenecid, an Oat inhibitor, was used to chemically inhibit Oatmediated renal transport in monkey and rat, while cimetidine was used to chemically inhibit Oct-mediated renal transport in rat. The administration of probenecid significantly decreased the renal clearance of PNU-288034 and increased the plasma exposure in monkey ( Figure 7 ). The total plasma AUC 0-∞ was increased from 15.2 ± 5.5 µg·h/mL to 26.1 ± 1.9 µg·h/mL (p<0.05) while the plasma clearance was decreased from 11.8 ± 3.7
This article has not been copyedited and formatted. The final version may differ from this version. and plasma free fraction (fu). Renal secretion in proximal tubular cells is mainly attributed to renal transporters, and thus depends on the transporter kinetics, plasma free fraction, and blood flow rate (Li et al., 2006) . In the present study the net secretion (CL r /GFR) of PNU-288034 was evident as the renal clearance was greater than GFR*fu, too high for the compound to be considered for further clinical development. Although renal clearance in human has been predicted successfully using physiologically based allometric procedures, the mechanism of clearance may complicate the interspecies scaling (Dedrick et al., 1970; Mahmood, 1998) . In this study renal secretion in human was approximately 2-fold higher than that observed in rat (Figure 3 ), indicating that the total and renal clearances predicted from rat data underestimated the values in human.
Given that the high renal clearance limited the clinical development of PNU-288034, these results illustrate how transporter-mediated renal secretion can complicate extrapolation from preclinical to clinical studies, and obscure the accurate prediction of human pharmacokinetics.
In order to elucidate the uptake transporter(s) potentially governing the active renal secretion of PNU-288034 in human and preclinical species, we conducted in vitro large contributor to the in vivo findings regarding the reduction of plasma clearance in rat, the involvement of P-gp and BCRP were theoretically expected to compensate for the inhibition of MATE1, given the compensatory effects previously observed in renal drug transport systems (El-Sheikh et al., 2008) . Surprisingly, compensatory effects were not evident as the inhibition by cimetidine was comparable to probenecid, suggesting that the exclusive collaboration of OAT3 and MATE1, but not P-gp or BCRP, govern the vectorial transport of PNU-288034. While the failure of P-gp and BCRP to compensate for brush-border membrane efflux remains to be explained, the difference in pH between the intra-and extra-cellular environments might alter the substrate specificity of P-gp or BCRP for PNU-288034 in an in vivo situation. In this regard, caution should still be exercised since the in vitro spectrum of transporter involvement may not necessarily translate directly to all in vivo situations.
Species differences in renal transporter expression (Buist and Klaassen, 2004; Terada et al., 2006) have long been recognized and can complicate pharmacokinetic scaling from preclinical species to human. In the present studies, the renal secretion of PNU-288034 was examined across species and extensive renal secretion was found in rat, monkey, and human, but not dog. Among the species tested, the monkey results were most similar to human and hence could provide the best pharmacokinetic prediction regarding the OAT3/MATE1-mediated renal secretion of PNU-288034 in human ( Figure   3 ). These results are also consistent with previous findings that indicate monkey is a good predictor of renal organic anion uptake in human (Tahara et al., 2005; Tahara et al., 2006a) . However, active renal secretion was not observed in dog (CL r /GFR<1), suggesting that significant interspecies differences in OAT3/MATE1-mediated PNUThis article has not been copyedited and formatted. The final version may differ from this version. Table 2 with coefficients of variation (CV%) of 12.6, 4.1, and 6.1% for rat, dog, and monkey, respectively. The CV% for human renal clearance measurements (Table 1 ) was 7 to 25% for the dose range of 100 to 1500 mg. Plasma and urine samples were collected and concentration-time curves were determined.
TABLES
Pharmacokinetic parameters were derived as described in the materials and methods.
Absolute oral bioavailability (F) was calculated using dose and AUC values. 
